Comparison of the Fibroblast Growth Factor (FGF -23) and Beta 2 microglobulin (β2M) levels in patients of chronic kidney disease (CKD) undergoing Renal Replacement Therapy (Haemodialysis vs Hemodiafiltration)
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- DGAFMS
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- Levels of FGF-23 and Beta 2 microglobulin
研究概览
简要总结
Chronic kidney disease is associated with higher rates of cardiovascular morbidities and mortalities as compared to general population. One of the proposed mechanism is poor clearance of fibroblast growth factor -23, beta 2 microglobulin, leptin, myoglobin etc with use of conventional haemodialysis and peritoneal dialysis. With introduction of online haemodiafiltration ( HDF) there have studies mentioning decrease in complications like anemia, mineral bone disease , cardiovascular illnesses and mortality since above mentioned molecules are removed by convection only. Hence to prolong lifespan of CKD patients, the role of middle molecule clearance needs to be explored,
研究设计
- 研究类型
- Interventional
- 分配方式
- Not Applicable
- 盲法
- Not Applicable
入排标准
- 年龄范围
- 18.00 Year(s) 至 80.00 Year(s)（—）
- 性别
- All
入选标准
- •Eligible adults of CKD 5D aged at least 18 years of age who have been initiated on any one of the two modalities of dialysis Individual should have functional AV fistula with blood flow more than 300 ml/min.
排除标准
- •Patients not having AV Fistula as vascular access in HDF and HD group
- •Patients not giving written informed consent will be excluded.
结局指标
主要结局
Levels of FGF-23 and Beta 2 microglobulin
时间窗: At Initiation of dialysis modality(0 week) and six(6) weeks
次要结局
未报告次要终点